Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,025 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT03454451 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | completed | Phase 1 | 117 | Corvus Pharmaceuticals, Inc.INDUSTRY | 2 | Dec 21, 2023 | clinicaltrials |
| NCT03229278 |
| Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma |
| completed |
| Phase 1 |
| 14 |
| Rutgers, The State University of New JerseyOTHER |
| 1 |
| Dec 6, 2023 |
| clinicaltrials |
| NCT03792347 | Preoperative Anti-PD-1 Antibody Combined With Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus(PALACE-1) | completed | Phase 1 | 20 | Hecheng Li M.D., Ph.DOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT00019578 | Stereotactic Radiosurgery in Treating Patients With Brain Tumors | completed | Phase 1 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03735628 | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | completed | Phase 1 | 16 | BayerINDUSTRY | 2 | Oct 6, 2023 | clinicaltrials |
| NCT03452332 | Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers | completed | Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04601402 | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | completed | Phase 1 | 11 | Genome & CompanyINDUSTRY | 1 | Aug 8, 2023 | clinicaltrials |
| NCT03215810 | Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT04452214 | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | completed | Phase 1 | 19 | Cantargia ABINDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04572100 | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer | completed | Phase 1 | 50 | University of ChicagoOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT01824901 | Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT02949700 | Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 26 | Baylor College of MedicineOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01935921 | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2023 | clinicaltrials |
| NCT01711541 | Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2023 | clinicaltrials |
| NCT02575404 | GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | completed | Phase 1 | 36 | Providence Health & ServicesOTHER | 1 | Jun 5, 2023 | clinicaltrials |
| NCT03733210 | Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer | completed | Phase 1 | 14 | Andrei IagaruOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT03758781 | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors | completed | Phase 1 | 12 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04413214 | Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial | completed | Phase 1 | 9 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01515137 | Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 47 | University of PittsburghOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03888092 | Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification | completed | Phase 1 / Phase 2 | 81 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 21, 2023 | clinicaltrials |
| NCT03689192 | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors | completed | Phase 1 | 13 | Herlev HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT01846091 | Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer | completed | Phase 1 | 12 | Mayo ClinicOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT02158234 | Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT03129061 | Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) | completed | Phase 1 | 15 | CellSight Technologies, Inc.INDUSTRY | 1 | Dec 5, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT02764593 | Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer | completed | Phase 1 | 40 | RTOG Foundation, Inc.OTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT03502148 | Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma(PRV111) | completed | Phase 1 / Phase 2 | 10 | Privo TechnologiesINDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT01592721 | Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 6 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 21, 2022 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02531906 | Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation | completed | Phase 1 | 60 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT02775812 | Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2022 | clinicaltrials |
| NCT04293679 | Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With isSCC | completed | Phase 1 / Phase 2 | 25 | SirnaomicsINDUSTRY | 1 | Jun 9, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT02178072 | Window Trial 5-aza in HNSCC, T-tare | completed | Phase 1 | 18 | Yale UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT01332266 | E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 95 | Eisai Inc.INDUSTRY | 4 | Jan 3, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT02636036 | Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors(SPICE) | completed | Phase 1 | 51 | Akamis BioINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT00660218 | A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer | completed | Phase 1 / Phase 2 | 53 | State University of New York - Upstate Medical UniversityOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03100045 | Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)(ART-AIN) | completed | Phase 1 | 18 | Johns Hopkins UniversityOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT01353625 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | completed | Phase 1 | 118 | CelgeneINDUSTRY | 4 | Oct 5, 2021 | clinicaltrials |
| NCT01816984 | PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | completed | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Oct 5, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Dec 21, 2023source: clinicaltrials